Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Samuel S EngelShailaja SuryawanshiSusanna R StevensRobert G JosseJan H CornelNeli JakubonieneAxel RiefflinTsvetalina TankovaJulio WainsteinEric D PetersonRury R Holmannull null

Published in: Diabetes, obesity & metabolism (2017)

Participants in TECOS with CKD had higher incidences of serious adverse events and diabetes complications than those without CKD. Treatment with sitagliptin was generally well tolerated, with no meaningful differences in safety outcomes observed between those with CKD assigned to sitagliptin or placebo.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
cardiovascular disease
glycemic control
clinical trial
metabolic syndrome
combination therapy
adipose tissue
phase iii
smoking cessation